ABUS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

599.59K

-61.78%

-0.035

-49.93%

399.96K

-77.32%

-0.040

-69.28%

199.62K

-98.15%

-0.040

-498.15%

Estimates Revision

The market is revising Upward the revenue expectations for Arbutus Biopharma Corporation (ABUS) for FY2025, with the revenue forecasts being adjusted by 0.45% over the past three months. During the same period, the stock price has changed by 9.84%.

Revenue Estimates for FY2025

Revise Upward

+0.45%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.01%

In Past 3 Month

Stock Price

Go Up

+9.84%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Arbutus Biopharma Corp (ABUS.O) is -30.19, compared to its 5-year average forward P/E of -8.78. For a more detailed relative valuation and DCF analysis to assess Arbutus Biopharma Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.78

Current PE

-30.19

Overvalued PE

-1.86

Undervalued PE

-15.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.07

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.39

Undervalued EV/EBITDA

-7.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

88.91

Current PS

642.12

Overvalued PS

230.17

Undervalued PS

-52.35

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ABUS News & Events

Events Timeline

No data

News

6.0

2025-11-14Benzinga

Chardan Capital Reaffirms Buy Rating for Arbutus Biopharma with $5 Price Target Intact

9.5

2025-08-06NASDAQ.COM

Arbutus (ABUS) Q2 Revenue Surges 529%

9.5

2025-08-06NASDAQ.COM

Arbutus Biopharma Corp. Q2 Earnings Summary

People Also Watch

Frequently Asked Questions

What is Arbutus Biopharma Corp (ABUS) stock price today?

The current price of ABUS is 4.69 USD — it has increased 0.86 % in the last trading day.

What is Arbutus Biopharma Corp (ABUS)'s business?

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

What is the price predicton of ABUS Stock?

Wall Street analysts forecast ABUS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABUS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Arbutus Biopharma Corp (ABUS)'s revenue for the last quarter?

Arbutus Biopharma Corp revenue for the last quarter amounts to 529.00K USD, decreased -60.49 % YoY.

What is Arbutus Biopharma Corp (ABUS)'s earnings per share (EPS) for the last quarter?

Arbutus Biopharma Corp. EPS for the last quarter amounts to -0.04 USD, decreased -60.00 % YoY.

What changes have occurred in the market's expectations for Arbutus Biopharma Corp (ABUS)'s fundamentals?

How many employees does Arbutus Biopharma Corp (ABUS). have?

Arbutus Biopharma Corp (ABUS) has 44 emplpoyees as of January 09 2026.

What is Arbutus Biopharma Corp (ABUS) market cap?

Today ABUS has the market capitalization of 894.31M USD.